Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

16 results about "Hepatitis E virus" patented technology

The hepatitis E virus (HEV) is the causative agent of hepatitis E. It is of the species Orthohepevirus A. The global burden of infections from the two major genotypes (1 and 2) is estimated at 20 million per year, leading to 70,000 deaths and 3,000 stillbirths.

Synthetic rocaglates with broad-spectrum antiviral activities and uses thereof

PendingUS20260115213A1Organic active ingredientsOrganic chemistryCrimean Congo hemorrhagic fever virusHaemorrhagic fever
Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses, Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatitis E virus, and other RNA viruses. Also described herein are synthetic rocaglate compositions, uses thereof, and methods for reducing or inhibiting translation initiation of a messenger ribonucleic acid (mRNA) of a virus in a host cell or organism infected by the virus.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT +1

Primers, probes and kits for detection of hepatitis delta virus

The application provides a hepatitis E virus nucleic acid detection primer, probe and kit, wherein according to a target sequence of a hepatitis E virus gene, a primer and a probe sequence in an asymmetric primer ERA detection system are designed, screened, and optimized in terms of an upstream primer ratio, a downstream primer ratio and an amplification reaction system, so that the primer and the probe can specifically recognize a nucleic acid sequence of the hepatitis E virus, non-specific binding with other irrelevant nucleic acids is reduced, and thus the specificity of detection is improved; meanwhile, efficient amplification of the hepatitis E virus nucleic acid is realized, and even in the case of extremely low content of the virus nucleic acid, the hepatitis E virus nucleic acid can be accurately detected, and thus the sensitivity and the amplification efficiency of detection are improved.
Owner:SUZHOU MUNICIPAL HOSPITAL +1

Primer probe combination, kit and method for detecting eight porcine viruses

The invention belongs to the technical field of biological detection, and particularly relates to a primer probe combination, a kit and a method for detecting eight porcine viruses. Specific primers and probes are designed for porcine circovirus type 2, porcine circovirus type 3, African swine fever virus, rotavirus, porcine hepatitis E virus, classical swine fever virus, norovirus and fiveleaf virus, and the kit is used for detecting eight viruses of pigs and has the advantages of high specificity, high sensitivity, stable effect and simplicity and convenience in operation; according to the method, eight infection pathogens can be detected, and the method is of great significance to the domestic pig feeding industry and wild boar epidemic disease monitoring and controlling work.
Owner:KUNMING MEDICAL UNIVERSITY

A mRNA based on hevorf2 truncated protein, preparation method and application thereof

The application provides mRNA based on HEV ORF2 truncated protein, a preparation method and application thereof, the mRNA based on HEV ORF2 truncated protein includes 5'UTR region, SP fragment, 3'UTR region, 3' terminal poly A tail, gene for encoding hepatitis E virus ORF2 truncated protein and 5' cap structure, the hepatitis E virus ORF2 truncated protein is ORF2-239aa protein or ORF2-549aa protein, the nucleotide sequence of the gene for encoding the ORF2-239aa protein is shown as SEQ ID NO.1, the nucleotide sequence of the gene for encoding the ORF2-549aa protein is shown as SEQ ID NO.2, the application has application value in hepatitis E research and vaccine creation, and can greatly promote the transformation application of vaccine.
Owner:XIANGHU LABORATORY

Hepatitis E virus-like particles (VLPs) derived from consensus sequences

Virus-Like Particles derived from the subfamilies, Parahepevirinae, which infect trout and salmon, and the Orthohepevirinae, which infect mammals and birds, particularly those of the species Paslahepevirus balayani, which can cause acute hepatitis in humans and several mammalian species, and chronic conditions in immunocompromised patients are also disclosed. Major aspects of the invention relate to compositions of Virus-Like Particles comprising viral capsid proteins capable of assembly in cultured cells that may be purified, disassembled, and reassembled in the presence of other molecules suitable for use as therapeutic drug products to facilitate the targeting and delivery of cargo molecules to specific cells or tissues, or as antigenic agents designed to stimulate responses to heterologous epitopes exposed on the surfaces of Virus-Like Particles. Preferred aspects relate to functional capsids comprising polypeptide sequences comprising one or more amino acid substitutions, insertions, or deletions of amino acid encoded by a consensus of ORF2 genes, wherein said variant polypeptides are functionally-similar or have enhanced properties compared to capsid polypeptides encoded by naturally-occurring viruses obtained from clinical samples or prototype Hepatitis E Viruses (HEV). Other aspects include the design and assembly of modified vectors to facilitate the basic and applied studies leading to the development and commercialization of novel drug products, and as tools advancing the interests of institutions involved in animal and human healthcare.
Owner:NOVO CAPSID TECHNOLOGIES LLC

Bivalent vaccine as well as preparation method and application thereof

The invention provides a bivalent vaccine which comprises a rabbit hemorrhagic syndrome virus antigen, a rabbit hepatitis E virus antigen and a microbial freeze-dried slow-release agent, and provides a preparation method which comprises the following steps: culturing the rabbit hepatitis E virus by using passage cells, obtaining the rabbit hepatitis E virus antigen, inoculating the rabbit hemorrhagic syndrome virus, and carrying out freeze-drying on the rabbit hemorrhagic syndrome virus. A rabbit hemorrhagic syndrome virus antigen is obtained, the rabbit hemorrhagic syndrome virus antigen and a rabbit hepatitis E virus antigen are mixed in proportion, a freeze-drying protective agent is supplemented, and the bivalent vaccine is obtained. The invention further provides an application experiment result of the compound, and the compound is used for preventing or treating rabbit hemorrhagic syndrome and rabbit hepatitis E. According to the invention, the two antigens are proportioned properly, so that the prepared vaccine at least achieves the efficacy of preventing and controlling immune epidemic diseases. The bivalent vaccine provided by the invention can prevent two diseases by one injection, reduce immune stimulation, continuously enhance the immune effect of a body, promote the body to generate better immune response, reduce the immune cost, simplify the immune procedure, and is more economical and reliable.
Owner:JILIN JIANZHU UNIVERSITY

Primer group, probe and detection method for lesser panda-derived hepatitis E virus and parainfluenza 5 virus

The invention relates to a primer group, a probe and a detection method for a lesser panda-derived hepatitis E virus and a parainfluenza 5 virus, the primer group and the probe can simultaneously and specifically recognize the lesser panda-derived hepatitis E virus and the parainfluenza 5 virus by a one-tube method, do not generate cross reaction with other common pathogens, have high specificity and sensitivity, and can be used for detecting the lesser panda-derived hepatitis E virus and the parainfluenza 5 virus. According to the detection method formed on the basis of the primer group and the probe, detection can be completed within 20 min under the constant-temperature condition, and a rapid pathogen diagnosis method and apparatus are provided for zoos, wild animal rescue centers and other conservation institutions.
Owner:GUANGZHOU ZOO (BRANDED AS GUANGZHOU WILDLIFE RES CENT)

Use of YAP pathway activator in preparation of Anti-hepatotropic virus medicament

PCT designated stageWO2025247037A1Organic active ingredientsDigestive systemHepatitis A virusesHepatitis B virus
A use of a YAP pathway activator in the preparation of an anti-hepatotropic virus medicament. In in vivo and in vitro hepatotropic virus replication models, it has been found that using the YAP pathway activator can significantly inhibit the replication of hepatotropic viruses such as hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, and hepatitis E virus and the expression of viral antigens. The antiviral effect of the activator is mainly achieved by means of regulation of the YAP signaling pathway and the fact that inhibiting YAP can restore viral replication. The described YAP pathway activator may be specifically a LATS1 / 2 kinase inhibitor, such as TDI-011536 or TRULI. The YAP pathway activator has no significant cytotoxicity and has a good antiviral effect.
Owner:FUDAN UNIVERSITY

Oligonucleotide composition, kit and application

The invention relates to the technical field of biological detection, and discloses an oligonucleotide composition, a kit and application. The composition disclosed by the invention can be used for rapidly and simultaneously detecting salmonella, shigella, entamoeba histolytica, vibrio cholerae, hepatitis A virus and hepatitis E virus in a sample with high specificity, and has relatively high sensitivity and stability. Compared with the traditional detection methods such as pathogen separation, genome sequencing and the like, the efficiency of identifying and detecting salmonella, shigella, entamoeba histolytica, vibrio cholerae, hepatitis A virus and hepatitis E virus by adopting the composition disclosed by the invention is effectively improved, the detection process is simple and convenient to operate, and the composition is suitable for large-scale popularization and application.
Owner:SANSURE (SHANGHAI) GENE TECH LTD

Vesicle for transporting target protein as well as preparation method and application of vesicle

PendingCN121472331ASsRNA viruses positive-sensePeptide/protein ingredientsReceptorCell culture supernatant
The invention discloses an exogenous gene delivery method, which comprises the following steps of: transfecting vesicles by using a fusion expression vector or a co-expression vector of an ORF3 protein gene of hepatitis E virus and an exogenous gene to generate cells, purifying cell culture supernatant by using a differential ultracentrifugation method to obtain vesicles, transfecting vesicle recipient cells by using the vesicles, and transferring the vesicles to obtain the exogenous gene. And further transferring an exogenous gene product into recipient cells. The invention also discloses a gene editing method, which comprises the following steps of: preparing a carrier which contains the fusion gene of the ORF3 protein of the hepatitis E virus and the Cas9 protein, inserting independently expressed sgDNA, transfecting vesicles by using the carrier to generate cells, purifying cell culture supernatant by using a differential ultracentrifugation method to obtain the vesicles, transfecting vesicle recipient cells by using the vesicles, and obtaining the gene editing product. And target genes corresponding to the sgDNA are edited in recipient cells. The method disclosed by the invention has an application prospect.
Owner:HARBIN VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER HARBIN BRANCH CENTER)

Antigen for detecting hepatitis e virus igm and preparation method and application thereof

ActiveCN119390790BVirus peptidesFermentationDimerIgm antibody
The application provides an antigen for detecting hepatitis E virus IgM and a preparation method and application thereof, relates to the technical field of biotechnology, and comprises the following (A) or (B); (A) a protein composed of the amino acid sequence shown in SEQ ID NO. 1; (B) a protein composed of the C terminal of the amino acid sequence shown in SEQ ID NO. 2 and the N terminal of the amino acid sequence shown in SEQ ID NO. 1. It is found that the ORF2aa417-660 antigen and the ORF2aa417-660 antigen added with a beta-fold structure sequence can be used as a point membrane raw material for detecting IgM antibodies in a colloidal gold product, the positive detection rate is high, the false positive rate is low, and the sensitivity is obviously better than that of the ORF2aa459-606 antigen. In particular, the ORF2aa417-660 antigen added with the beta-fold structure sequence is helpful to the formation of a dimer and a multimer of the antigen, and further enhances the immunogenicity of the antigen.
Owner:SURE BIOTECH (HANGZHOU) LTD

Hepatitis e virus-like particles (VLPS) derived from consensus sequences

PendingAU2024400878A1HeterologousChronic hepatitis
Virus-Like Particles derived from the subfamilies, Parahepevirinae and Orthohepevirinae, particularly those of the species Paslahepevirus balayani, which can cause acute hepatitis in humans and several mammalian species, and chronic conditions in immunocompromised patients are disclosed. Compositions of VirusLike Particles comprising viral capsid proteins capable of assembly in cultured cells that may be purified, disassembled, and reassembled in the presence of other molecules suitable for use as therapeutic drug products to facilitate the targeting and delivery of cargo molecules to specific cells or tissues, or as antigenic agents designed to stimulate responses to heterologous epitopes exposed on the surfaces of Virus- Like Particles are provided. Functional capsids comprising polypeptide sequences comprising amino acid substitutions, insertions, or deletions of amino acid encoded by a consensus of ORF2 genes, that are functionally-similar or have enhanced properties compared to capsid polypeptides encoded by naturally-occurring viruses obtained from clinical samples or prototype Hepatitis E Viruses (HEV) are provided.
Owner:NOVO CAPSID TECHNOLOGIES LLC

Primer set for detecting porcine hev whole genome, kit comprising the primer set and application

The application discloses a primer set for detecting a whole genome of a pig HEV, a kit comprising the primer set and application. The primer set comprises nucleotide sequences as shown in SEQ ID NO. 1-62, the primer set is designed for amplification fragments of 450 bp of a whole gene of the pig HEV and 650 bp of a non-conserved region, is divided into two sets of shingle degenerate primers, comprises five primer groups of A, B, C, D and E, and five amplification primer pools are constructed by using the five primer groups, so that the primer set can cover the complete genome of different strain types of the pig HEV. The application also establishes a method for sequencing the whole genome of the pig hepatitis E virus by using multiplex targeted RT-PCR and nanopore sequencing based on the primer set. The method is rapid, sensitive and specific, can be used for rapidly obtaining the whole genome information of the pig hepatitis E virus in a sample, and provides a reliable technical means for tracing the pig hepatitis E virus and accurately determining the genotype.
Owner:SCIENCE & TECHNOLOGY RESEARCH CENTER OF CHINA CUSTOMS

A capture probe combination, kit and use thereof in whole genome sequencing of hepatitis E virus

PendingCN122279100AGenomic sequencingNucleotide
This invention relates to the field of gene detection technology, and more particularly to a capture probe combination, a kit, and its application in hepatitis E virus whole-genome sequencing. The probe combination comprises probes with nucleotide sequences as shown in SEQ ID NO.1-SEQ ID NO.951. The applications include: (1) detecting hepatitis E virus, or preparing products for detecting hepatitis E virus; (2) whole-genome sequencing of hepatitis E virus, or preparing products for whole-genome sequencing of hepatitis E virus. This invention provides a set of probes for whole-genome sequencing of hepatitis E virus, which can specifically enrich ultra-low copy number hepatitis E virus genomes from high background host nucleic acids, and thus has significant application value in hepatitis E virus detection in various scenarios such as clinical diagnosis, epidemic tracing, virus mutation monitoring, food safety testing, and basic research.
Owner:STATION OF VIRUS PREVENTION & CONTROL CHINA DISEASES PREVENTION & CONTROL CENT

Primer probe combination and method for detecting hepatitis E virus and application

The invention discloses a primer probe combination for detecting hepatitis E virus, a method and application. The nucleotide sequence of the primer comprises sequences as shown in SEQ ID NO. 1 to SEQ ID NO. 4; the nucleic acid sequence of the fluorescent probe comprises a sequence as shown in SEQ ID NO. 5 to SEQ ID NO. 6. The primer probe combination and the detection method provided by the invention can cover each gene subtype of genotype 3 and genotype 4 hepatitis E viruses and perform typing on the genotype 3 and genotype 4 hepatitis E viruses, and are high in sensitivity and simple to operate.
Owner:SHANGHAI MUNICIPAL CENT FOR DISEASE CONTROL & PREVENTION

Primer group for detecting porcine HEV whole genome, kit comprising primer group and application

The invention discloses a primer group for detecting a porcine HEV whole genome, a kit comprising the primer group and application. The primer group comprises nucleotide sequences as shown in SEQ ID NO.1-62, the primer group is designed aiming at amplified fragments of 450bp of a whole gene and 650bp of a non-conserved region of the pig HEV, and is divided into two sets of imbalanobis degenerate primers, the two sets of imbalanobis degenerate primers comprise five primer groups A, B, C, D and E, five amplification primer pools are respectively constructed by the five primer groups, and the primer groups can be ensured to cover complete genomes of different plant types of viruses of the pig HEV. The invention also establishes a method for sequencing the whole genome of the porcine hepatitis E virus by multi-targeting RT-PCR (Reverse Transcription-Polymerase Chain Reaction) and nanopore sequencing on the basis of the primer group. The method is quick, sensitive and specific, can be used for quickly acquiring the whole-genome information of the porcine hepatitis E virus in a sample, and provides a reliable technical means for tracing the source of the porcine hepatitis E virus and accurately judging the genotype.
Owner:SCIENCE & TECHNOLOGY RESEARCH CENTER OF CHINA CUSTOMS